Thus, our results indicated that FOXO3a is a negative regulator of VEGF-A/NRP1 and that dysregulated FOXO3a/VEGF-A/NRP1 signaling contributes to disease progression of breast cancer. This evidence concerns the gene FOXO3 and breast carcinoma.